Bausch + Lomb 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Bausch + Lomb reported second quarter 2026 revenue of $1.394 billion, up 8% on a constant currency basis, driven by broad-based growth across pharmaceuticals, vision care, and surgical segments.
- Adjusted EBITDA grew 28% year over year to $246 million, with an adjusted EBITDA margin of 17.6%, up 260 basis points year over year.
- Cash flow from operations more than tripled from $45 million in Q1 to $161 million in Q2, with adjusted free cash flow of $90 million and net leverage reduced by one full turn to approximately 4.7 times.
- Pharmaceuticals revenue increased 14%, led by dry eye products Meibo and Xiidra, with Meibo growing 44% to $91 million and MyEyeDr. revenue up 6%.
- Vision care revenue rose 4%, with contact lenses up 5% driven by strong growth in Daily Cy Fi (16%), Biotrue (13%), and Ultra (9%).
- Surgical revenue increased 16%, with premium intraocular lenses (IOLs) growing 175% and implantables up 64% compared to prior year and 37% versus Q2 2020 baseline.
- Adjusted gross margin improved by 160 basis points to 62.2%, driven by favorable mix and productivity initiatives.
- Adjusted R&D investment increased 19% to $114 million, representing 7.5% to 8% of revenue, supporting a diversified pipeline.
- Adjusted SG&A margin improved by approximately 130 basis points, reflecting structural cost improvements.
- Adjusted EPS was $0.16, compared to $0.07 in the prior year quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. Welcome to Bausch + Lomb's second quarter 2026 earnings call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to George Gadkowski, Vice President of Investor Relations and Business Insights. Please go ahead. Thank you.
Good morning everyone. Welcome to our second quarter 2026 financial results conference call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Brent Saunders, Chief Financial Officer, Mr. Sam Eldessouky, and President of Surgical, Mr. Luc Bonnefoy. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section. Before we begin, I would like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking legend at the beginning of our presentation, as it contains important information. This presentation contains non-GAAP financial measures and ratios. For more information about these measures and ratios, please refer to slide one of the presentation.
Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website. The financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter unless required by law and not to update or affirm guidance other than through broadly disseminated public disclosure. With that, it's my pleasure to turn the call over to Brent.
Thank you, George. Thanks to everyone joining us today, especially my colleagues around the world whose commitment and passion are at the heart of everything we achieve. Today's presentation will follow a familiar format. I'll start with an overview of the quarter and Sam will walk through the details of another beat and raise. We'll then cover growth drivers by segment, including an update from our Surgical President, Luc Bonnefoy. The format won't be the only thing that sounds familiar. Leveraging the P&L margin expansion, broad-based revenue growth, improved cash flow generation. These have been themes since we unveiled our three-year plan for growth at Investor Day last November. In the second quarter, progress continued at an accelerated pace. You see that here. 8% constant currency revenue growth once again reflects consistent performance across our pharmaceuticals, vision care, and surgical segments.
Continued momentum from each business creates a stronger, more resilient company and more durable growth profile over time. 28% adjusted EBITDA growth and 17.6% adjusted EBITDA margin demonstrate the quality of the growth we referenced last quarter. Building on the operating leverage and margin expansion that began in the second half of 2025. Of note, SG&A continues to decline as a percentage of revenue, which Sam will cover later. If you're wondering where our confidence in meeting or exceeding our three-year plan comes from, look no further than these charts. On the left, you see the story we've been telling. Constant currency revenue growth accelerating from 6% in the first quarter to 8% in the second, and adjusted EBITDA margin expanding from 16.1% to 17.6%, an increase of 150 basis points.
Growth and margin moving in the same direction quarter after quarter. The more important story is on the right, because expanding margins only matter if they translate into cash, and they are. Adjusted cash flow from operations more than tripled from $45 million in the first quarter to $161 million in the second. Year to date cash conversion is approximately 46% in line with our expectations. Stronger cash generation translated into meaningful balance sheet progress, helping us lower our leverage by a full turn from this point last year. Credibility doesn't come from making bold promises. It comes from making the right commitments and delivering on them quarter after quarter, year after year. That's been our approach from day one. We communicate our priorities, align our teams behind them, and execute with discipline.
The say-do mentality has helped us build trust with stakeholders, and more importantly, has positioned us to create sustainable long-term value. In other words, companies earn credibility through consistency. You see that discipline reflected across these pillars. Second quarter growth was broad-based with standout double-digit performance from pharmaceuticals and surgical. The top-line momentum translated directly into profitability. $246 million in adjusted EBITDA up 28% year-over-year. Again, growth and margin working together consistent with the operating model we outlined. Our selling and operational execution is showing up in the numbers too. In surgical, the accelerating mix shift towards premium IOLs is expanding both revenue and margin.
In pharmaceuticals, MIEBO and XIIDRA both delivered strong revenue growth, the result of a refreshed market access approach and disciplined commercial execution. Last quarter, we laid the groundwork for the introduction of Orphia, an AI-powered digital health platform designed to reduce the operational burden between physicians and their patients. Orphia was built to serve every eye care provider, no matter what they prescribe or what products they use. It fills a real void, and it's already generating encouraging feedback within the eye care community. In our third pillar, what you're seeing is a pipeline delivering on two time horizons at once. In the near term, we have concrete milestones expected to land this year.
We filed our FDA submission for our ELIOS implant-free MIGS excimer laser in the second quarter. Readouts for our dual-action dry eye candidate and ocular surface pain candidate are expected in the second half of this year. Looking further out, we have programs that are expected to extend our run rate well into the next decade and into categories where the unmet need is only growing. We've been in this business long enough to know that not every program will make it to the finish line. That's the nature of innovation in eye health. That's precisely why we've built the pipeline the way we have. Breadth and depth aren't buzzwords for us. They're a deliberate design choice. A robust, diversified pipeline means we're never dependent on any single asset to deliver. It's what gives us confidence in sustained cadence of milestones quarter after quarter, year after year.
You see that breadth and depth here. Rather than the linear pipeline timeline you're used to seeing from us, this view organizes our assets by category, from dry eye disease and surgical, to consumer eye health, contact lenses, retinal disease, and increasingly, AI and computational biology. We believe this distinguishes Bausch + Lomb among eye care companies. Depth of portfolio is only half the story. The other half is where the world is heading. An aging global population, the rapid rise of childhood myopia, longer screen time across every age group, a growing prevalence of dry eye and retinal disease. These aren't temporary tailwinds. They're structural shifts in demand. Each of the programs you see here is designed to meet one of them. As a reminder, we're expanding EBITDA margins while increasing our R&D spend, which is another way of saying we're not sacrificing innovation for metrics.
This is what balance looks like. Every segment growing, every segment contributing. Surgical revenue up 16% on a constant currency basis. Pharmaceuticals up 14%. Vision care up 4%. The headline isn't just the numbers are strong, it's that they're coming from everywhere. Pharmaceuticals continued its momentum with MIEBO and XIIDRA once again anchoring the segment's growth. Vision care delivered another quarter of dependable performance, with contact lenses up 5% on a constant currency basis, powered by ongoing strength in our daily SiHy portfolio. I'd like to spend a moment on surgical. Last quarter, we said the U.S. field force rebuild was the right strategic decision. That the business would strengthen sequentially through the balance of the year. One quarter later, 16% constant currency revenue growth. 17% versus 2Q 2024.
Our premium IOL portfolio delivered 175% reported revenue growth. Premium mix continued to expand both in the U.S. and globally. Every one of the leading signals we pointed to last quarter, productivity, execution, sales trajectory, is now translating directly into results. The results support the strategic actions we took. We expect surgical to remain a meaningful growth driver from here. We're entering the second half of the year with real momentum behind us. Sam, over to you for financial drivers and our refreshed outlook.
Thank you, Brent, and good morning, everyone. Before we begin, please note that all of my comments today will be focused on growth expressed on a constant currency basis, unless specifically indicated otherwise. In addition, all references to adjusted EBITDA will exclude acquired IPR&D. Q2 was another strong quarter and further evidence of the momentum across the business. We delivered meaningful top-line growth and margin expansion. We also generated strong operating leverage with adjusted EBITDA up 28% on a reported basis. Revenue growth and margin expansion are now also translating into stronger cash generation and deleveraging to strengthen the balance sheet. This is the progression we outlined. First, rejuvenating revenue growth. Second, expanding margins. Now converting the stronger earnings into cash and improving our leverage. We are doing this while continuing to invest in the R&D pipeline.
Stepping back, this is the fourth consecutive quarter of delivering on our priorities. This strengthens our confidence that we remain on track to achieve our three-year targets. Turning now to our financial results on slide 9. Total company revenue for the quarter was $1.394 billion, up 8%, driven by broad-based growth across all our segments. Foreign exchange was a tailwind to revenue of approximately $12 million in the second quarter. Let's dive into each of our segments in more detail. Vision Care's second quarter revenue of $784 million increased by 4%, with growth in both consumer and contact lenses. Let me go over a few highlights in our Vision Care segment. The consumer business grew 3% in the quarter. The consumer dry eye portfolio delivered $123 million of revenue in the second quarter, up 5%.
Growth was driven by Blink, which was up 12%, and Artelac, which was up 3%. LUMIFY generated $63 million of revenue, up 2%. Eye vitamins, PreserVision, and Ocuvite delivered $104 million of revenue in the quarter, up 1% on a reported basis. Overall, we saw consumer demand strengthen through the quarter, with healthy consumption trends exiting Q2 and continuing into July. Contact lens revenue grew 5% in the second quarter, driven by broad-based performance across all key product families and all geographies. Across the product families, DAILIES AquaComfort Plus grew 16%, Biotrue is up 13%, and ULTRA is up 9%. The business delivered balanced growth across geographies, with the U.S. up 5% and international up 6%. The international performance was strong across all regions. EMEA at 11%, Latin America at 7%, Canada 11%, and Asia-Pac 3%. Moving to the surgical segment.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
